Citations

Showing 10 of 108094 citations.

Evaluation of Galcanezumab for the Prevention of Episodic Migraine
Stauffer, Virginia L. , Zhang, Qi , Carter, Jeffrey N., Conley, Robert R., Dodick, David W. , Ailani, Jessica

Mayo Clinic

JAMA Neurology | May 29, 2018 | Volume: 75 | Issue: 9 | Pages: 1080

10.1001/jamaneurol.2018.1212 | PMID 29813147 Get It

Big Data and Predictive Analytics
Shah, Nilay D. , Kent, David M. , Steyerberg, Ewout W. , Kent, David M

Mayo Clinic

JAMA | May 29, 2018 | Volume: 320 | Issue: 1 | Pages: 27

10.1001/jama.2018.5602 | PMID 29813156 Get It

Human Pegivirus infection and lymphoma risk and prognosis: a North American study
Famà, Angelo , Xiang, Jinhua , Link, Brian K. , Allmer, Cristine, Klinzman, Donna, Feldman, Andrew L. , Nowakowski, Grzegorz S. , Liebow, Mark , Maurer, Matthew J. , Ansell, Stephen M. , Novak, Anne J. , Asmann, Yan W. , Call, Timothy G. , Stapleton, Jack T. , Maurer, Matthew , Cerhan, James R , Feldman, Andrew L , Link, Brian K , Larson, Melissa C. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

British Journal of Haematology | May 29, 2018 | Volume: 182 | Issue: 5 | Pages: 644-653

10.1111/bjh.15416 | PMID 29808922 Get It

SummaryWe evaluated the association of Human Pegivirus (HPgV) viraemia with risk of developing lymphoma, overall and by major subtypes. Because this virus has also been associated with better prognosis in the setting of co‐infection with human immunodeficiency virus, we further assessed the association of HPgV with prognosis. We used risk factor data and banked plasma samples from 2094 lymphoma cases newly diagnosed between 2002 and 2009 and 1572 frequency‐matched controls. Plasma samples were tested for HPgV RNA by reverse transcription polymerase chain reaction (RT‐PCR), and those with RNA concentrations <5000 genome equivalents/ml were confirmed using nested RT‐PCR methods. To assess the role of HPgV in lymphoma prognosis, we used 2948 cases from a cohort study of newly diagnosed lymphoma patients (included all cases from the case‐control study). There was a positive association of HPgV viraemia with risk of lymphoma overall (Odds ratio = 2·14; 95% confidence interval [CI] 1·63–2·80; P < 0·0001), and for all major subtypes except Hodgkin lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma, and this was not confounded by other lymphoma risk factors. In contrast, there was no association of HPgV viraemia with event‐free survival (Hazard ratio [HR] = 1·00; 95% CI 0·85–1·18) or overall survival (HR = 0·97; 95% CI 0·79–1·20) for lymphoma overall, or any of the subtypes. These data support the hypothesis for a role of HPgV in the aetiology of multiple lymphoma subtypes.
Three-dimensional shear wave elastography for differentiation of breast lesions: An initial study with quantitative analysis using three orthogonal planes
Wang, Qiao , Li, Xiao‐Long , He, Yaping , Chen, Shigao , Zhao, Chong‐Ke , Bo, Xiao‐Wan, Ren, Weiwei , Zhou, Bangguo, Xu, Hui‐Xiong , Alizad, Azra , Guo, Le‐Hang

Mayo Clinic

Clinical Hemorheology and Microcirculation | May 29, 2018 | Volume: 71 | Issue: 3 | Pages: 311-324

10.3233/ch-180388 | PMID 29865044 Get It

40 YEARS OF IGF1: PAPP-A and cancer
Conover, Cheryl A. , Oxvig, Claus

Mayo Clinic

Journal of Molecular Endocrinology | May 29, 2018 | Volume: 61 | Issue: 1 | Pages: T1-T10

10.1530/jme-17-0236 | PMID 29844094 Get It

The zinc metalloproteinase, PAPP-A, enhances local insulin-like growth factor (IGF) action through cleavage of inhibitory IGF-binding proteins, thereby increasing IGF available for IGF receptor-mediated cell proliferation, migration and survival. In many tumors, enhanced IGF receptor signaling is associated with tumor growth, invasion and metastasis. We will first discuss PAPP-A structure and function, and post-translational inhibitors of PAPP-A expression or proteolytic activity. We will then review the evidence supporting an important role for PAPP-A in many cancers, including breast, ovarian and lung cancer, and Ewing sarcoma.
Palliative Care Use Among Patients With Solid Cancer Tumors
Osagiede, Osayande , Spaulding, Aaron , Frank, Ryan D. , Merchea, Amit , Uitti, Ryan J. , Colibaseanu, Dorin T, Spaulding, Aaron C. , Kelley, Scott R. , Osagiede, Osayande , Spaulding, Aaron , Colibaseanu, Dorin , Ailawadhi, Sikander

Mayo Clinic

Journal of Palliative Care | May 29, 2018 | Volume: 33 | Issue: 3 | Pages: 149-158

10.1177/0825859718777320 | PMID 29807486 Get It

Background: Palliative care has been increasingly recognized as an important part of cancer care but remains underutilized in patients with solid cancers. There is a current gap in knowledge regarding why palliative care is underutilized nationwide. Objective: To identify the factors associated with palliative care use among deceased patients with solid cancer tumors. Methods: Using the 2016 National Cancer Data Base, we identified deceased patients (2004-2013) with breast, colon, lung, melanoma, and prostate cancer. Data were described as percentages. Associations between palliative care use and patient, facility, and geographic characteristics were evaluated through multivariate logistic regression. Results: A total of 1 840 111 patients were analyzed; 9.6% received palliative care. Palliative care use was higher in the following patient groups: survival >24 months (17% vs 2%), male (54% vs 46%), higher Charlson-Deyo comorbidity score (16% vs 8%), treatment at designated cancer programs (74% vs 71%), lung cancer (76% vs 28%), higher grade cancer (53% vs 24%), and stage IV cancer (59% vs 13%). Patients who lived in communities with a greater percentage of high school degrees had higher odds of receiving palliative care; Central and Pacific regions of the United States had lower odds of palliative care use than the East Coast. Patients with colon, melanoma, or prostate cancer had lower odds of palliative care than patients with breast cancer, whereas those with lung cancer had higher odds. Conclusions: Palliative care use in solid cancer tumors is variable, with a preference for patients with lung cancer, younger age, known insurance status, and higher educational level.
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
Tse, Chung Sang , Loftus, Edward V. , Raffals, Laura E. , Gossard, Andrea A., Lightner, Amy L. , Tse, C S , Lightner, A L , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 29, 2018 | Volume: 48 | Issue: 2 | Pages: 190-195

10.1111/apt.14829 | PMID 29808485 Get It

SummaryBackgroundPrimary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (IBD) with no known cure.AimTo evaluate the effect of biological therapies on PSC progression in IBD patients.MethodsWe performed a retrospective cohort study of 88 cases (75 unique patients with 12 patients treated >1 biologics) of IBD (48 ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with concomitant PSC who received biological therapy (42 infliximab, 19 adalimumab, 27 vedolizumab) between June 2002 and October 2017. Hepatic biochemistries were compared using the paired t‐test (patients served as their own controls) ≤3 months before and 6‐8 and 12‐14 months after biological initiation. Radiographic information of biliary stenosis and liver fibrosis were obtained via abdominal ultrasound, abdominal magnetic resonance imaging and magnetic resonance elastography.ResultsUse of adalimumab was associated with a significant decrease in alkaline phosphatase (ALP) after 6‐8 months (P = 0.03; mean change −70 U/L, standard deviation [SD] 88 U/L) compared to vedolizumab (mean change +50 U/L, SD 142 U/L) or infliximab (mean change +37 U/L, SD 183 U/L) but the change was not significant after 12‐14 months (P = 0.24). No significant decreases were observed with AST, ALT, total or direct bilirubin, elastography score or radiographic imaging of biliary tree dilation/strictures with any biological therapy after 6‐8 or 12‐14 months.ConclusionsCurrent evidence suggests that biological therapies used for the treatment of IBD are not effective treatments for PSC. Further study is needed to elucidate any potential beneficial effect of adalimumab on PSC.
Social Medicine: Twitter in Healthcare
Pershad, Yash , Hangge, Patrick T., Albadawi, Hassan , Öklü, Rahmi , Oklu, Rahmi

Mayo Clinic

Journal of Clinical Medicine | May 29, 2018 | Volume: 7 | Issue: 6 | Pages: 121

10.3390/jcm7060121 | PMID 29843360 Get It

Social media enables the public sharing of information. With the recent emphasis on transparency and the open sharing of information between doctors and patients, the intersection of social media and healthcare is of particular interest. Twitter is currently the most popular form of social media used for healthcare communication; here, we examine the use of Twitter in medicine and specifically explore in what capacity using Twitter to share information on treatments and research has the potential to improve care. The sharing of information on Twitter can create a communicative and collaborative atmosphere for patients, physicians, and researchers and even improve quality of care. However, risks involved with using Twitter for healthcare discourse include high rates of misinformation, difficulties in verifying the credibility of sources, overwhelmingly high volumes of information available on Twitter, concerns about professionalism, and the opportunity cost of using physician time. Ultimately, the use of Twitter in healthcare can allow patients, healthcare professionals, and researchers to be more informed, but specific guidelines for appropriate use are necessary.
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
Friedenberg, Keith, Younes, Ziad , Seidler, Ursula , Bhandari, Bal Raj, Wang, Ke , Wendt, Emily, McKevitt, Matt, Zhao, Sally, Sundy, John S., Lee, Scott D. , Loftus, Edward V. , Loftus, Edward V , Schreiber, Stefan , Siegel, Corey A

Mayo Clinic

Journal of Crohn's and Colitis | May 28, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ecco-jcc/jjy070 | PMID 29846530 Get It

Comparing the Hospital-Acquired Condition Reduction Program and the Accreditation of Cancer Program: A Cross-sectional Study
Spaulding, Aaron , Paul, Rachel, Colibaseanu, Dorin , Spaulding, Aaron , Paul, Rachel A

Mayo Clinic

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | May 28, 2018 | Volume: 55 | Issue: No issue available | Pages: No page available

10.1177/0046958018770294 | PMID 29806532 Get It

Under the Hospital-Acquired Condition Reduction Program (HACRP), introduced by the Affordable Care Act, the Centers for Medicare and Medicaid must reduce reimbursement by 1% for hospitals that rank among the lowest performing quartile in regard to hospital-acquired conditions (HACs). This study seeks to determine whether Accredited Cancer Program (ACP) hospitals (as defined by the American College of Surgeons) score differently on the HACRP metrics than nonaccredited cancer program hospitals. This study uses data from the 2014 American Hospital Association Annual Survey database, the 2014 Area Health Resource File, the 2014 Medicare Final Rule Standardizing File, and the FY2017 HACRP database (Medicare Hospital Compare Database). The association between ACPs, HACs, and market characteristics is assessed through multinomial logistic regression analysis. Odds ratios and 95% confidence intervals are reported. Accredited cancer hospitals have a greater risk of scoring in the Worse outcome category of HAC scores, vs Middle or Better outcomes, compared with nonaccredited cancer hospitals. Despite this, they do not have greater odds of incurring a payment reduction under the HACRP measurement system. While ACP hospitals can likely improve scores, questions concerning the consistency of the message between ACP hospital quality and HACRP quality need further evaluation to determine potential gaps or issues in the structure or measurement. ACP hospitals should seek to improve scores on domain 2 measures. Although ACP hospitals do likely see more complex patients, additional efforts to reduce surgical site infections and related HACs should be evaluated and incorporated into required quality improvement efforts. From a policy perspective, policy makers should carefully evaluate the measures utilized in the HACPR.